EHA 2026: Novel Cell Therapy Approaches in AML

At the EHA Congress 2026, Mika Kontro, MD, PhD, Associate Professor and Head of the Clinical Trials Unit in Hematology, Helsinki University Hospital Comprehensive Cancer Center, Finland, presents preclinical data on the gamma delta T-cell therapy NAKU in acute myeloid leukemia. He discusses its potential in combination with azacitidine and venetoclax and the rationale for advancing this approach into clinical testing.